Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Rituximab Combined With Tacrolimus in the Treatment of Intermediate-to-high Risk Primary Membranous Nephropathy: A Randomized Clinical Trial

NCT05532111 is registered in ClinicalTrials.gov with RenJi Hospital as lead sponsor.

NCT NCT05532111
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05532111 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Rituximab Combined With Tacrolimus in the Treatment of Intermediate-to-high Risk Primary Membranous Nephropathy: A Randomized Clinical Trial
Lead sponsor
RenJi Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
September 1, 2022
Completion date
September 30, 2024
Enrollment
60 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

efficacy and safety